December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Five articles suggested by Yüksel Ürün
Dec 23, 2024, 12:11

Five articles suggested by Yüksel Ürün

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.

Five articles suggested by Yüksel Ürün

He suggested following few must-read papers on X:

1.”Genomic sequencing identified hereditary cancer risks in 9% of patients after uninformative gene panels. However, most findings lacked evidence-based guidelines.”

Clinical Utility of Genomic Sequencing for Hereditary Cancer Syndromes: An Observational Cohort Study.

Authors: Salma Shickh, et al.

 Five articles suggested by Yüksel Ürün

 

2.”SOLO3 Trial Update: Olaparib improved ORR & PFS vs. nonplatinum chemo in BRCA-mutated relapsed ovarian cancer. OS benefit seen in 2 prior chemo lines (HR: 0.83). BRCA reversion mutations may impact negative outcomes in ≥3 lines.”

Five articles suggested by Yüksel Ürün

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

Authors: Giovanni Scambia, et al.

Five articles suggested by Yüksel Ürün

3.”ENGOT-OV41/ANITA Trial Update: Adding atezolizumab to platinum-based chemo + maintenance niraparib did not improve PFS or ORR in late-relapsing recurrent ovarian cancer.”

Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

Authors: Antonio González-Martín, et al.

Five articles suggested by Yüksel Ürün

4.”Liquid Biopsy & MRD: ctDNA-based MRD detection in solid tumors can predict relapse months before imaging. A new era of post-adjuvant therapies may eliminate MRD.”

Minimal residual disease as a target for liquid biopsy in patients with solid tumours.

Authors: Klaus Pantel, et al.

Five articles suggested by Yüksel Ürün

5.”A game-changer for tailoring treatment in high-risk cases.”

 

Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum.

Authors: Johan Stranne, et al.

 Five articles suggested by Yüksel Ürün

More posts featuring Yüksel Ürün.